Galidesivir HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 328059

CAS#: 222631-44-9 (HCl)

Description: Galidesivir, also known as BCX4430 and Immucillin-A, is an antiviral drug and an adenosine analog. Galidesivir was originally intended as a treatment for Hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease. Galidesivir also shows broad-spectrum antiviral effectiveness against a range of other RNA virus families, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. BCX4430 has been demonstrated to protect against both Ebola and Marburg viruses in both rodents and monkeys, even when administered up to 48 hours after infection.

Chemical Structure

Galidesivir HCl
CAS# 222631-44-9 (HCl)

Theoretical Analysis

MedKoo Cat#: 328059
Name: Galidesivir HCl
CAS#: 222631-44-9 (HCl)
Chemical Formula: C11H16ClN5O3
Exact Mass: 265.1175
Molecular Weight: 301.731
Elemental Analysis: C, 43.79; H, 5.35; Cl, 11.75; N, 23.21; O, 15.91

Price and Availability

Size Price Availability Quantity
1.0mg USD 900.0 2 Weeks
Bulk inquiry

Related CAS #: 222631-44-9 (HCl)   249503-25-1 (free base)    

Synonym: Galidesivir; BCX4430; BCX 4430; BCX-4430. Immucillin-A.

IUPAC/Chemical Name: (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol hydrochloride


InChi Code: InChI=1S/C11H15N5O3.ClH/c12-11-8-6(14-3-15-11)4(1-13-8)7-10(19)9(18)5(2-17)16-7;/h1,3,5,7,9-10,13,16-19H,2H2,(H2,12,14,15);1H/t5-,7+,9-,10+;/m1./s1

SMILES Code: O[C@H]1[C@H](C2=CNC3=C(N)N=CN=C32)N[C@H](CO)[C@H]1O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 301.731 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Taylor R, Kotian P, Warren T, Panchal R, Bavari S, Julander J, Dobo S, Rose A, El-Kattan Y, Taubenheim B, Babu Y, Sheridan WP. BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public Health. 2016 May-Jun;9(3):220-6. doi: 10.1016/j.jiph.2016.04.002. PubMed PMID: 27095300; PubMed Central PMCID: PMC4937725.

2: Setlur AS, Naik SY, Skariyachan S. Herbal Lead as Ideal Bioactive Compounds Against Probable Drug Targets of Ebola Virus in Comparison with Known Chemical Analogue: A Computational Drug Discovery Perspective. Interdiscip Sci. 2016 Feb 8. [Epub ahead of print] PubMed PMID: 26857866.

3: Madelain V, Nguyen TH, Olivo A, de Lamballerie X, Guedj J, Taburet AM, Mentré F. Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. Clin Pharmacokinet. 2016 Aug;55(8):907-23. doi: 10.1007/s40262-015-0364-1. Review. PubMed PMID: 26798032.

4: Reina J. [Current status of drug treatment against the disease caused by the Ebola virus]. Rev Esp Quimioter. 2016 Feb;29(1):1-7. Spanish. PubMed PMID: 26785224.

5: De Clercq E. C-Nucleosides To Be Revisited. J Med Chem. 2016 Mar 24;59(6):2301-11. doi: 10.1021/acs.jmedchem.5b01157. Review. PubMed PMID: 26513594.

6: Janeba Z. Development of Small-Molecule Antivirals for Ebola. Med Res Rev. 2015 Nov;35(6):1175-94. doi: 10.1002/med.21355. Review. PubMed PMID: 26172225.

7: De Clercq E. Curious (Old and New) Antiviral Nucleoside Analogues with Intriguing Therapeutic Potential. Curr Med Chem. 2015;22(34):3866-80. Review. PubMed PMID: 26112146.

8: Bekerman E, Einav S. Infectious disease. Combating emerging viral threats. Science. 2015 Apr 17;348(6232):282-3. doi: 10.1126/science.aaa3778. PubMed PMID: 25883340; PubMed Central PMCID: PMC4419706.

9: Cardile AP, Mayers DL, Bavari S. Current status of chemically synthesized inhibitors of Ebola virus. Recent Pat Antiinfect Drug Discov. 2014;9(2):97-103. Review. PubMed PMID: 25808170.

10: Olszanecki R, Gawlik G. Pharmacotherapy of Ebola hemorrhagic fever: a brief review of current status and future perspectives. Folia Med Cracov. 2014;54(3):67-77. Review. PubMed PMID: 25694097.

11: De Clercq E. Ebola virus (EBOV) infection: Therapeutic strategies. Biochem Pharmacol. 2015 Jan 1;93(1):1-10. doi: 10.1016/j.bcp.2014.11.008. Review. PubMed PMID: 25481298.

12: Stock I. [Marburg and Ebola hemorrhagic fevers--pathogens, epidemiology and therapy]. Med Monatsschr Pharm. 2014 Sep;37(9):324-30; quiz 331-2. Review. German. PubMed PMID: 25282746.

13: Vere Hodge RA. Meeting report: 27th International conference on antiviral research, in Raleigh, NC, USA. Antiviral Res. 2014 Nov;111:143-53. doi: 10.1016/j.antiviral.2014.08.009. PubMed PMID: 25218950.

14: Julander JG, Bantia S, Taubenheim BR, Minning DM, Kotian P, Morrey JD, Smee DF, Sheridan WP, Babu YS. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model. Antimicrob Agents Chemother. 2014 Nov;58(11):6607-14. doi: 10.1128/AAC.03368-14. PubMed PMID: 25155605; PubMed Central PMCID: PMC4249364.

15: Wong G, Qiu X, Olinger GG, Kobinger GP. Post-exposure therapy of filovirus infections. Trends Microbiol. 2014 Aug;22(8):456-63. doi: 10.1016/j.tim.2014.04.002. Review. PubMed PMID: 24794572.

16: Harrington M. Small molecule, big advance against Marburg virus. Lab Anim (NY). 2014 Apr 21;43(5):154. doi: 10.1038/laban.536. PubMed PMID: 24751840.

17: Falzarano D, Feldmann H. Possible leap ahead in filovirus therapeutics. Cell Res. 2014 Jun;24(6):647-8. doi: 10.1038/cr.2014.49. PubMed PMID: 24732011; PubMed Central PMCID: PMC4042172.

18: Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014 Apr 17;508(7496):402-5. doi: 10.1038/nature13027. PubMed PMID: 24590073.

Additional Information

Related CAS#
249503-25-1 (Galidesivir free base)
222631-44-9 (Galidesivir hydrochloride)